

BEST AVAILABLE COPY

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Tapas Mukhopadhyay, *et al.*

Serial No.: 10/043,877

Filed: January 9, 2002

For: ANTIHELMINTHIC DRUGS AS A
TREATMENT FOR
HYPERPROLIFERATIVE DISEASES

Group Art Unit: 1642

Examiner: B. J. Fetterolf

Atty. Dkt. No.: INRP:095US

**SECOND DECLARATION OF TAPAS MUKHOPADHYAY, SUNIL CHADA, ABNER
MHASHILKAR, AND JACK A. ROTH UNDER 37 C.F.R. §1.131**

We, Tapas Mukhopadhyay, Sunil Chada, Abner Mhashilkar, and Jack A. Roth, hereby declare as follows:

1. We are the joint inventors of the subject matter claimed in the above-referenced patent application, U.S.S.N. 10/043,887, filed January 9, 2002.
2. We are submitting this declaration to set forth facts demonstrating that we both conceived the idea of the invention as reflected in the claims of the above-referenced patent application and determined that it functioned, prior to March 9, 1999.
3. Submitted as Exhibit 1 to this declaration is a copy of a FACS assay showing our experiments and results, entitled figures "1A" and "1B" which was prepared prior to March 9, 1999.

4. Submitted as Exhibit 2 to this declaration is a copy of our experiments and results in a study of the treatment of p53 wild type lung cancer cells with fenbendazole, which took place prior to March 9, 1999.

5. Exhibit 1 shows the results of our cell cycle analysis involving A549 (p53 wild type) non-small cell lung cancer (NSCLC) cells that have been treated with fenbendazole. The results show that the untreated A549 cells (A549C), have a standard profile of cells in various phases of the cell cycle, G1/S/G2, indicating a dominant G1 population. In contrast, the fenbendazole treated cells (A549 7EN) show a depression of both G2 and S phases and a G1 block. Furthermore, the fenbebdazole treated cells show a distinct sub-G0-G1 population indicative of apoptotic cells. We generated the results of this cell cycle analysis prior to March 9, 1999.

6. Exhibit 2 shows the results of our study of the treatment of p53 wild type lung cancer with fenbendazole. We determined that treatment of p53 wild type lung cancer cells with fenbendazole inhibits growth. The study evaluated growth of lung cancer cells or normal lung epithelium (NHBE) after treatment with fenbendazole (labeled FEN in the figure) and other agents. Both H1299 and H322 are p53 deficient NSCLC cells and show modest growth inhibition by fenbendazole after 5-7 days. In contrast, the p53 wild type cells A549 and H460 show dramatic inhibition of cell growth by fenbendazole that is evident by day 1-3 and 50-80% growth inhibition by day 5-7 of treatment. The control normal cells, NHBEX do not show growth inhibition by fenbendazole. We generated the results of this study prior to March 9, 1999.

7. All work disclosed in the invention disclosure form was conducted in the United States of America.

8. Therefore, the invention as reflected in the claims of the above-referenced patent application was reduced to practice prior to March 9, 1999.

9. We hereby declare that all statements made by our own knowledge are true and all statements made on information and belief are believed to be true and further that statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment under § 100 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issued thereon.

Date

Date

Date

Date


Tapas Mukhopadhyay

Sunil Chada

Abner Mhashilkar

Jack A. Roth

Attn: Dr. Monica De La Paz



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Tapas Mukhopadhyay, *et al.*

Group Art Unit: 1642

Serial No.: 10/043,877

Examiner: B. J. Fetterolf

Filed: January 9, 2002

Atty. Dkt. No.: INRP:095US

For: ANTIHELMINTHIC DRUGS AS A
TREATMENT FOR
HYPERPROLIFERATIVE DISEASES**SECOND DECLARATION OF TAPAS MUKHOPADHYAY, SUNIL CHADA, ABNER
MHASHILKAR, AND JACK A. ROTH UNDER 37 C.F.R. §1.131**

We, Tapas Mukhopadhyay, Sunil Chada, Abner Mhashilkar, and Jack A. Roth, hereby declare as follows:

1. We are the joint inventors of the subject matter claimed in the above-referenced patent application, U.S.S.N. 10/043,887, filed January 9, 2002.
2. We are submitting this declaration to set forth facts demonstrating that we both conceived the idea of the invention as reflected in the claims of the above-referenced patent application and determined that it functioned, prior to March 9, 1999.
3. Submitted as Exhibit 1 to this declaration is a copy of a FACS assay showing our experiments and results, entitled figures "1A" and "1B" which was prepared prior to March 9, 1999.

Tapas Mukhopadhyay

4. Submitted as Exhibit 2 to this declaration is a copy of our experiments and results in a study of the treatment of p53 wild type lung cancer cells with fenbendazole, which took place prior to March 9, 1999.

5. Exhibit 1 shows the results of our cell cycle analysis involving A549 (p53 wild type) non-small cell lung cancer (NSCLC) cells that have been treated with fenbendazole. The results show that the untreated A549 cells (A549C), have a standard profile of cells in various phases of the cell cycle, G1/S/G2, indicating a dominant G1 population. In contrast, the fenbendazole treated cells (A549 FEN) show a depression of both G2 and S phases and a G1 block. Furthermore, the fenbendazole treated cells show a distinct sub-G0-G1 population indicative of apoptotic cells. We generated the results of this cell cycle analysis prior to March 9, 1999.

6. Exhibit 2 shows the results of our study of the treatment of p53 wild type lung cancer with fenbendazole. We determined that treatment of p53 wild type lung cancer cells with fenbendazole inhibits growth. The study evaluated growth of lung cancer cells or normal lung epithelium (NHBE) after treatment with fenbendazole (labeled FEN in the figure) and other agents. Both H1299 and H322 are p53 deficient NSCLC cells and show modest growth inhibition by fenbendazole after 5-7 days. In contrast, the p53 wild type cells A549 and H460 show dramatic inhibition of cell growth by fenbendazole that is evident by day 1-3 and 50-80% growth inhibition by day 5-7 of treatment. The control normal cells, NHBE do not show growth inhibition by fenbendazole. We generated the results of this study prior to March 9, 1999.

7. All work disclosed in the invention disclosure form was conducted in the United States of America.

8. Therefore, the invention as reflected in the claims of the above-referenced patent application was reduced to practice prior to March 9, 1999.

9. We hereby declare that all statements made by our own knowledge are true and all statements made on information and belief are believed to be true and further that statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment under § 100 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issued thereon.

Date

Tapas Mukhopadhyay
Tapas Mukhopadhyay

Date

Sunil Chada

Date

Abner Mhashilkar

Date

Jack A. Roth



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Tapas Mukhopadhyay, *et al.*

Serial No.: 10/043,877

Filed: January 9, 2002

For: ANTIHELMINTHIC DRUGS AS A
TREATMENT FOR
HYPERPROLIFERATIVE DISEASES

Group Art Unit: 1642

Examiner: B. J. Fetterolf

Atty. Dkt. No.: INRP:095US

**SECOND DECLARATION OF TAPAS MUKHOPADHYAY, SUNIL CHADA, ABNER
MHASHILKAR, AND JACK A. ROTH UNDER 37 C.F.R. §1.131**

We, Tapas Mukhopadhyay, Sunil Chada, Abner Mhashilkar, and Jack A. Roth, hereby
declare as follows:

1. We are the joint inventors of the subject matter claimed in the above-referenced
patent application, U.S.S.N. 10/043,887, filed January 9, 2002.

2. We are submitting this declaration to set forth facts demonstrating that we both
conceived the idea of the invention as reflected in the claims of the above-referenced patent
application and determined that it functioned, prior to March 9, 1999.

3. Submitted as Exhibit 1 to this declaration is a copy of a FACS assay showing our
experiments and results, entitled figures "1A" and "1B" which was prepared prior to March 9,
1999.

4. Submitted as Exhibit 2 to this declaration is a copy of our experiments and results in a study of the treatment of p53 wild type lung cancer cells with fenbendazole, which took place prior to March 9, 1999.

5. Exhibit 1 shows the results of our cell cycle analysis involving A549 (p53 wild type) non-small cell lung cancer (NSCLC) cells that have been treated with fenbendazole. The results show that the untreated A549 cells (A549C), have a standard profile of cells in various phases of the cell cycle, G1/S/G2, indicating a dominant G1 population. In contrast, the fenbendazole treated cells (A549 7EN) show a depression of both G2 and S phases and a G1 block. Furthermore, the fenbebdazole treated cells show a distinct sub-G0-G1 population indicative of apoptotic cells. We generated the results of this cell cycle analysis prior to March 9, 1999.

6. Exhibit 2 shows the results of our study of the treatment of p53 wild type lung cancer with fenbendazole. We determined that treatment of p53 wild type lung cancer cells with fenbendazole inhibits growth. The study evaluated growth of lung cancer cells or normal lung epithelium (NHBE) after treatment with fenbendazole (labeled FEN in the figure) and other agents. Both H1299 and H322 are p53 deficient NSCLC cells and show modest growth inhibition by fenbendazole after 5-7 days. In contrast, the p53 wild type cells A549 and H460 show dramatic inhibition of cell growth by fenbendazole that is evident by day 1-3 and 50-80% growth inhibition by day 5-7 of treatment. The control normal cells, NHBEX do not show growth inhibition by fenbendazole. We generated the results of this study prior to March 9, 1999.

7. All work disclosed in the invention disclosure form was conducted in the United States of America.

8. Therefore, the invention as reflected in the claims of the above-referenced patent application was reduced to practice prior to March 9, 1999.

9. We hereby declare that all statements made by our own knowledge are true and all statements made on information and belief are believed to be true and further that statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment under § 100 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issued thereon.

Date

Tapas Mukhopadhyay

Date

Sunil Chada


Date

08/10/05

Abhir Mhashilkar

Date

Jack A. Roth



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Tapas Mukhopadhyay, *et al.*

Serial No.: 10/043,877

Filed: January 9, 2002

For: ANTIHELMINTHIC DRUGS AS A
TREATMENT FOR
HYPERPROLIFERATIVE DISEASES

Group Art Unit: 1642

Examiner: B. J. Fetterolf

Atty. Dkt. No.: INRP:095US

**SECOND DECLARATION OF TAPAS MUKHOPADHYAY, SUNIL CHADA, ABNER
MHASHILKAR, AND JACK A. ROTH UNDER 37 C.F.R. §1.131**

We, Tapas Mukhopadhyay, Sunil Chada, Abner Mhashilkar, and Jack A. Roth, hereby declare as follows:

1. We are the joint inventors of the subject matter claimed in the above-referenced patent application, U.S.S.N. 10/043,887, filed January 9, 2002.

2. We are submitting this declaration to set forth facts demonstrating that we both conceived the idea of the invention as reflected in the claims of the above-referenced patent application and determined that it functioned, prior to March 9, 1999.

3. Submitted as Exhibit 1 to this declaration is a copy of a FACS assay showing our experiments and results, entitled figures "1A" and "1B" which was prepared prior to March 9, 1999.

4. Submitted as Exhibit 2 to this declaration is a copy of our experiments and results in a study of the treatment of p53 wild type lung cancer cells with fenbendazole, which took place prior to March 9, 1999.

5. Exhibit 1 shows the results of our cell cycle analysis involving A549 (p53 wild type) non-small cell lung cancer (NSCLC) cells that have been treated with fenbendazole. The results show that the untreated A549 cells (A549C), have a standard profile of cells in various phases of the cell cycle, G1/S/G2, indicating a dominant G1 population. In contrast, the fenbendazole treated cells (A549 7EN) show a depression of both G2 and S phases and a G1 block. Furthermore, the fenbendazole treated cells show a distinct sub-G0-G1 population indicative of apoptotic cells. We generated the results of this cell cycle analysis prior to March 9, 1999.

6. Exhibit 2 shows the results of our study of the treatment of p53 wild type lung cancer with fenbendazole. We determined that treatment of p53 wild type lung cancer cells with fenbendazole inhibits growth. The study evaluated growth of lung cancer cells or normal lung epithelium (NHBE) after treatment with fenbendazole (labeled FEN in the figure) and other agents. Both H1299 and H322 are p53 deficient NSCLC cells and show modest growth inhibition by fenbendazole after 5-7 days. In contrast, the p53 wild type cells A549 and H460 show dramatic inhibition of cell growth by fenbendazole that is evident by day 1-3 and 50-80% growth inhibition by day 5-7 of treatment. The control normal cells, NHBE do not show growth inhibition by fenbendazole. We generated the results of this study prior to March 9, 1999.

7. All work disclosed in the invention disclosure form was conducted in the United States of America.

8. Therefore, the invention as reflected in the claims of the above-referenced patent application was reduced to practice prior to March 9, 1999.

9. We hereby declare that all statements made by our own knowledge are true and all statements made on information and belief are believed to be true and further that statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment under § 100 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issued thereon.

Date

Tapas Mukhopadhyay

Date


Sunil Chada

Date

Abner Mhashilkar

8-15-05


Date



Jack A. Roth

Exhibit 1

① A



18






Exhibit 2


H1299-FENBEN growth assay




H322-FENBEN growth assay




A549-FENBEN growth assay




H460 -FENBEN growth assay




NHBEc -FENBEN growth assay




H1299-FENBEN growth assay




H322-FENBEN growth assay




Group	Day 1	Day 3	Day 5	Day 7
Con- A549	~10	~25	~85	~115
dl 312	~15	~30	~90	~120
Adp53-1	~10	~25	~85	~115
p53-FEN	~10	~25	~85	~115
FEN	~10	~25	~85	~115
Lac Z	~10	~25	~85	~115
dl-FEN	~10	~25	~85	~115



H460 -FENBEN growth assay



HNBEc -FENBEN growth assay



NHBE

7-en 105mg
 dldl312 mol=1
 V3 mol=1

	Day 1		Day 3		Day 5		Day 7							
Control	x2	30	15	x2	50	25	x3	70	53	x5	79	44		
2		26	13		46	23		67	50		82	103		
3		30	15		56	28		62	47		84	105		
4		x2			x2			x3			x5			
5	Yes	20	10		42	21		70	53		81	101		
6		14	7		40	20		65	49		76	95		
7		19	10		38	19		60	45		82	103		
8														
9		x2			x2			x3			x5			
10	dcs	19	10		32	16		56	42		72	90		
11		24	12		30	15		52	39		69	86		
12		23	12		35	18		50	37		70	88		
13														
14		x2			x2			x3			x5			
15	Basal	22	11		48	24		71	53		80	100		
16		24	12		52	26		62	47		81	101		
17		24	12		50	25		60	45		78	98		
18														
19		x2			x2			x3			x5			
20	V3	20	10		40	20		51	38		66	83		
21		15	8		42	21		55	41		62	78		
22		19	10		44	22		52	39		68	85		
23		x2			x2			x3			x5			
24	d-F	19	10		30	10		38	29		57	71		
25		17	9		20	10		48	30		55	69		
26		20	10		24	12		39	29		58	73		
27														
28		x1			x1			x2			x3			
29		17	4		18	5		22	11		32	24		
30	d-F	10	3		19	5		27	14		39	29		
31		9	2		19	5		24	12		40	30		

EFFICIENCY LINE 22-206

H460

	Day 1		Day 3		Day 5		Day 7				
Control	25	19	x3	52	39	x5	70	88	x10	98	245
x3	29	22		56	42		75	94		100	250
	26	20		50	38		72	90		92	230
7m	x3		x3			x3			x5		
	18	14		21	16		28	21		40	50
	17	13		19	14		30	23		38	48
	10	8		22	17		27	20		42	53
dl312	x3		x3			x5			x10		
	30	23		54	41		72	90		96	240
	27	20		44	33		68	85		98	245
	28	21		50	38		74	93		101	252
B. Bal	x3		x3			x5			x10		
	21	16		49	37		62	78		82	208
	27	20		47	35		68	85		90	225
	26	20		44	33		68	85		89	223
x3	x3		x3			x5			x10		
	30	23		52	39		71	89		95	238
	27	20		41	31		70	88		97	242
	25	19		49	37		68	85		99	248
1-F	x3		x3			x3			x5		
	15	11		20	15		29	22		38	48
	18	14		20	15		29	22		40	50
	16	12		18	14		30	23		38	48
y-F	x1		x1			x2			x2		
	7	2		7	2		15	8		20	10
	8	2		10	3		17	9		20	10
	6	2		9	2		15	8		24	12

H1299

	Day 1		Day 3		Day 5		Day 7		
	x2		x2		x3		x3		
Initial	25	13	41	24	60	45	80	60	
1	30	15	42	21	62	47	88	66	
2	26	13	44	22	63	47	91	68	
3	x2		x2		x3		x3		
4	30	15	34	17	58	44	67	50	
5	23	12	38	19	56	42	70	53	
6	24	12	40	20	56	42	70	53	
7									
8	x2		x2		x3		x3		
9	20	10	40	20	62	47	89	67	
10	24	12	41	21	60	45	84	63	
11	20	10	40	20	60	45	86	65	
12									
13	x2		x2		x3		x3		
14	23	12	41	21	59	44	86	65	
15	20	10	39	20	60	45	90	68	
16	24	12	36	18	64	48	88	66	
17									
18	x2		x2		x3		x3		
19	10	5	11	6	20	15	30	23	
20	15	8	19	10	22	17	36	27	
21	17	9	19	10	24	18	39	29	
22									
23	x2		x2		x3		x3		
24	20	10	32	16	55	41	72	54	
25	23	12	42	21	57	43	74	56	
26	25	13	36	18	55	41	70	53	
27	x2		x1		x2		x2		
28	9	2	10	3	20	10	30	15	
29	8	2	12	3	20	10	27	14	
30	13	3	16	4	24	12	29	15	

EFFICIENCY LINE 22-206



AS49

	Day 1		Day 3		Day 5		Day 7		
Central	x2		x3		x5		x5		
2	27	14	38	29	66	82	89	111	
3	30	15	42	32	60	75	90	113	
4	30	15	40	30	63	79	92	115	
5	x2		x3		x5		x5		
6	17	9	25	19	35	44	51	64	
7	19	10	27	20	36	45	52	65	
8	19	10	20	15	30	38	55	69	
9									
10	x2		x3		x5		x5		
11	27	14	38	29	60	75	80	100	
12	26	13	44	33	62	78	88	110	
13	30	15	41	31	64	80	90	113	
14									
15	x2		x3		x5		x5		
16	24	12	41	31	58	73	90	113	
17	28	14	38	29	63	79	87	109	
18	25	13	40	30	60	75	81	101	
19									
20	x2		x3		x5		x5		
21	28	14	40	30	62	78	90	113	
22	26	13	40	30	62	78	91	114	
23	24	12	39	29	60	75	90	113	
24									
25	x2		x3		x5		x5		
26	18	8	28	21	34	43	54	68	
27	17	9	30	23	37	46	52	65	
28	20	10	25	19	33	41	54	68	
29	x1		x1		x2		x3		
30	10	3	10	3	14	7	19	14	
31	8	2	12	3	16	8	20	15	
	8	2	9	2	13	7	22	17	

EFFICIENCY LINE 22-206



del 3/12

Bagal

V3

d-F

V-F

H 322 J

EFFICIENCY LINE 22-206

			Day 1	sd			
Con-NHB	15	13	15	14.33333	0.942809	25	23
FEN	10	7	10	9	1.414214	21	20
dl 312	10	12	12	11.33333	0.942809	16	15
Lac Z	11	12	12	11.66667	0.471405	24	26
Adp53-1	10	8	10	9.33333	0.942809	20	21
dl- FEN	10	9	10	9.66667	0.471405	10	10
p53-FEN	4	3	2	3	0.816497	5	5

			Day 1	sd			
Con-H460	19	22	20	20.33333	1.247219	39	42
FEN	14	13	8	11.66667	2.624669	16	14
dl 312	23	20	21	21.33333	1.247219	41	33
Lac Z	16	20	20	18.66667	1.885618	37	35
Adp53-1	23	20	19	20.66667	1.699673	39	31
dl- FEN	11	14	12	12.33333	1.247219	15	15
p53-FEN	2	2	2	2	0	2	3

			Day 1	sd			
Con- A549	14	15	15	14.66667	0.471405	29	32
FEN	9	10	10	9.666667	0.471405	19	20
dl 312	14	13	15	14	0.816497	29	33
Lac Z	12	14	13	13	0.816497	31	29
Adp53-1	14	13	12	13	0.816497	30	30
dl- FEN	8	9	10	9	0.816497	21	23
p53-FEN	3	2	2	2.333333	0.471405	3	3

			Day 1	sd			
Con-H322	15	12	12	13	1.414214	29	30
FEN	12	10	10	10.66667	0.942809	25	26
dl 312	11	12	13	12	0.816497	30	31
Lac Z	10	10	12	10.66667	0.942809	27	28
Adp53-1	10	9	12	10.33333	1.247219	31	32
dl- FEN	9	10	10	9.666667	0.471405	23	26
p53-FEN	8	9	9	8.666667	0.471405	10	10

			Day 1	sd			
Con-H129	13	15	13	13.66667	0.942809	24	21
FEN	15	12	12	13	1.414214	17	19
dl 312	10	12	10	10.66667	0.942809	20	21
Lac Z	12	10	12	11.33333	0.942809	21	20
Adp53-1	5	8	9	7.333333	1.699673	6	10
dl- FEN	10	12	13	11.66667	1.247219	16	21
p53-FEN	2	2	3	2.333333	0.471405	3	3

Day 3			sd	Day 5			sd
28	25.33333	2.054805	53	50	47	50	2.44949
19		0.816497	53	49	45	49	3.265986
18	16.33333	1.247219	42	39	37	39.33333	2.054805
25	25	0.816497	53	47	45	48.33333	3.399346
22	21	0.816497	38	41	39	39.33333	1.247219
12	10.66667	0.942809	29	30	29	29.33333	0.471405
5	5	0	11	14	12	12.33333	1.247219

Day 3			sd	Day 5			sd
38	39.66667	1.699673	88	94	90	90.66667	2.494438
17	15.66667	1.247219	21	23	20	21.33333	1.247219
38	37.33333	3.299832	90	85	93	89.33333	3.299832
33	35	1.632993	78	85	85	82.66667	3.299832
37	35.66667	3.399346	89	88	85	87.33333	1.699673
14	14.66667	0.471405	22	22	23	22.33333	0.471405
2	2.333333	0.471405	8	9	8	8.333333	0.471405

Day 3			sd	Day 5			sd
30	30.33333	1.247219	82	75	79	78.66667	2.867442
15	18	2.160247	44	45	38	42.33333	3.091206
31	31	1.632993	75	78	80	77.66667	2.054805
30	30	0.816497	73	79	75	75.66667	2.494438
29	29.66667	0.471405	78	78	75	77	1.414214
19	21	1.632993	43	46	41	43.33333	2.054805
2	2.666667	0.471405	7	8	7	7.333333	0.471405

Day 3			sd	Day 5			sd
33	30.66667	1.699673	50	44	47	47	2.44949
23	24.66667	1.247219	38	43	41	40.66667	2.054805
26	29	2.160247	46	47	45	46	0.816497
29	28	0.816497	47	44	42	44.33333	2.054805
33	32	0.816497	47	45	45	45.66667	0.942809
28	25.66667	2.054805	36	38	35	36.33333	1.247219
14	11.33333	1.885618	15	15	12	14	1.414214

Day 3			sd	Day 5			sd
22	22.33333	1.247219	45	47	47	48.33333	0.942809
20	18.66667	1.247219	44	42	42	42.66667	0.942809
20	20.33333	0.471405	47	45	45	45.66667	0.942809
18	19.66667	1.247219	44	45	48	45.66667	1.699673
10	8.666667	1.885618	15	17	18	16.66667	1.247219
18	18.33333	2.054805	41	43	41	41.66667	0.942809
4	3.333333	0.471405	10	10	12	10.66667	0.942809

		Day 7	sd
99	103	105	102.3333 2.494438
101	95	103	99.66667 3.399346
90	86	88	88 1.632993
100	101	98	99.66667 1.247219
83	78	85	82 2.94392
71	69	73	71 1.632993
24	29	30	27.66667 2.624669

		Day 7	sd
245	250	230	241.6667 8.498366
50	48	53	50.33333 2.054805
240	245	252	245.6667 4.921608
205	225	223	217.6667 8.993825
238	242	248	242.6667 4.109609
48	50	48	48.66667 0.942809
10	10	12	10.66667 0.942809

		Day 7	sd
111	113	115	113 1.632993
64	65	69	66 2.160247
100	110	113	107.6667 5.557777
113	109	101	107.6667 4.988877
113	114	113	113.3333 0.471405
68	65	68	67 1.414214
14	15	17	15.33333 1.247219

		Day 7	sd
100	101	105	102 2.160247
96	95	90	93.66667 2.624669
100	100	102	100.6667 0.942809
99	98	86	94.33333 5.906682
103	89	88	93.33333 6.847546
80	99	88	89 7.788881
20	20	21	20.33333 0.471405

		Day 7	sd
60	66	68	64.66667 3.399346
50	53	53	52 1.414214
67	63	65	65 1.632993
65	68	66	66.33333 1.247219
23	27	29	26.33333 2.494438
54	56	53	54.33333 1.247219
15	14	15	14.66667 0.471405

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.